Affiliations: [a] Department of Urology, Haikou Municipal Hospital, Haikou, Hainan, China | [b] Department of Neurology, Haikou Municipal Hospital, Haikou, Hainan, China
Correspondence:
[*]
Corresponding author: Zhi-Ming Bai, Department of Urology, Haikou Municipal Hospital, Haikou, Hainan 570208, China. E-mail:[email protected]
Note: [1] Cai Lv and Yuan Huang are the co-first author.
Abstract: Salidroside has been reported to exhibit anticancer properties. This study
aimed to investigate the effects of salidroside on renal cell carcinoma
growth. Cell viability and proliferation was assessed by Cell Counting
Kit-8 and colony formation assays in A498 and 786-0 cells. The effects of
salidroside on in vivo tumor growth were also assessed in a mouse xenograft model of
renal cell carcinoma. Flow cytometry was used to analyze cell cycle and
apoptosis and protein levels were determined by western blotting. Salidroside
reduced cell viability and colony formation in both cell lines in a
concentration- and time-dependent manner. Tumor growth was also suppressed
in the mouse model. Furthermore, salidroside induced significant G1 phase
cell cycle arrest and induced apoptosis in both A498 and 786-0 cells. Higher
concentrations of salidroside reduced the levels of phosphorylated signal
transducer and activator of transcription 3 (STAT3) and Janus kinase 2
(JAK2). These results suggested that salidroside produced potent anticancer
properties in renal cell carcinoma by modulating JAK2/STAT3 signaling.
Administration of salidroside to patients with renal cell carcinoma might
provide a promising therapeutic strategy for this malignancy.
